Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
Retatrutide represents the current leading edge of incretin agonist design the first triple-receptor agonist in late-stage clinical trials
Chronic Weight Management: In June 2021, the FDA approved semaglutide (Wegovy) at a higher dose of 2.4 mg for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia
Systemic skin sensitivity affects areas far from the injection site
Clinical response
T., Torriani, M., Kleiner, D
US$ 29.07
US$ 20.55
US$ 22.42
US$ 22.37
US$ 27.08
US$ 26.66
